Ventyx Biosciences, Inc. (VTYX) Tops Q2 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/4/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Ventyx Biosciences Reports Second Quarter 2025 Financial Results and Highlights Recent Corporate Progress
August 7, 2025 4:05 PM EDTPositive topline Phase 2a biomarker data position VTX3232 as a potential disease-modifying therapy for patients with Parkinsons disease Data from the Phase 2 study of VTX2735 in patients with recurrent pericarditis expected in Q4 2025 Phase 2 study of VTX3232 in participants with obesity and cardiometabolic risk factors is fully-enrolled and on track to yield topline data in early Q4 2025 Cash, cash equivalents and marketable securities balance of $209.0M as of
June 30, 2025 expected to fund planned operations into at least H2 2026
SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Ventyx... More
